Skip to main content
. 2022 May 24;12:7802. doi: 10.1038/s41598-022-11696-6

Figure 4.

Figure 4

Kaplan–Meier curves showing time to metastatic disease in trastuzumab naïve and trastuzumab-treated patients. Comparison of patients with (a,b) BMI < 25 kg/m2 versus BMI ≥ 25 kg/m2; (c,d) Analysis of trastuzumab-treated only patients stratified by BMI comparing B-CLS ≤ 1 versus B-CLS > 1.